Table 2—

Lung function, NO parameters and inflammatory markers in exhaled breath condensate(EBC) and symptom scores in 40 patients with chronic obstructive pulmonary disease before and after 4 weeks of treatment with inhaled fluticasone

Post-bronchodilator FEV1 % pred61.5±2.562.8±2.40.300#
Post-bronchodilator FEV1/FVC0.51±0.020.51±0.020.284#
Post-bronchodilator FEF75% % pred26.4±2.026.5±1.70.924#
Post-bronchodilator RV % pred137.7±5.7129.3±4.90.005#
Post-bronchodilator Raw % pred213.4±15.2212.2±12.70.892#
FeNO0.05 ppb10.3 (6.0–17.2)7.2 (5.1–12.2)0.001
J′aw,NO nL·s−10.35 (0.11–0.57)0.19 (0.10–0.38)0.001
J′aw,NO(TMAD) nL·s−10.60 (0.19–0.97)0.32 (0.17–0.65)0.001
CA,NO ppb3.1 (2.3–3.7)2.9 (2.4–3.8)0.328
CA,NO(TMAD) ppb2.6 (1.9–3.5)2.5 (2.2–3.4)0.811
EBC LTB4 pg·mL−16.7 (5.0–9.0)6.4 (4.6–8.9)0.501
EBC cysLT pg·mL−17.5 (1.0–13.8)7.7 (1.0–14.4)0.985
EBC 8-isoprostane pg·mL−19.5 (7.8–14.6)9.7 (7.9–12.7)0.541
SGRQ symptom score54.1±3.738.7±3.80.001#
SGRQ activity score47.9±3.043.6±3.40.050#
SGRQ impact score23.0±2.222.0±2.40.568#
SGRQ total score35.7±2.331.3±2.60.010#
  • Data are presented as mean±sem or median (interquartile range), unless otherwise stated. FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; FEF75%: forced expiratory flow when 75% of vital capacity is exhaled; RV: residual volume; Raw: airway resistance; FeNO0.05: fractional exhaled NO concentration at exhalation flow rate of 0.05 L·s−1; J'aw,NO: bronchial NO flux; J'aw,NO(TMAD): bronchial NO flux adjusted for trumpet shape airways and axial diffusion; CA,NO: alveolar NO concentration; CA,NO(TMAD): alveolar NO concentration adjusted for trumpet shape airways and axial diffusion; LTB4: leukotriene B4; cysLT: cysteinyl leukotriene; SGRQ: St George's Respiratory Questionnaire. #: paired t-test; : Wilcoxon’s test. Values in bold are statistically significant.